USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in.
/PRNewswire/ Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) is pleased to announce preclinical data demonstrating the effectiveness of uTREAT®.
Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023